Genmab Says Achieves $30 Mln Milestone In DARZALEX Collaboration With Janssen

(RTTNews) - Genmab A/S (GMXAY.PK, GNMSF.OB) said that it has achieved a US$30 million milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech, Inc. The milestone payment was triggered by the first commercial sale of DARZALEX in Europe.

The European Commission (EC) recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX (daratumumab) for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.

This milestone was included in Genmab's previously issued financial guidance for 2016.